Rare Disease

News

CHMP backs Roche's Enspryng for rare nerve disease NMOSD

Roche's Enspryng has been recommended for approval in the EU for treating neuromyelitis optica spectrum disorder (NMOSD), extending the treatment options for people with the life-threatenin

News

Calliditas eyes 2022 approval in EU for rare kidney disease ...

Calliditas Therapeutics is on course to launch its first product, Nefecon for rare disease primary IgA nephropathy (IgAN), in the first half of 2022 after getting the green light for an acc

News

Jazz lifted by third EU approval for GW Pharma's Epidyolex

GW Pharmaceuticals' Epidyolex has been approved in the EU for a third epilepsy indication, giving a boost for the company ahead of its $7.2 billion

News

Businessmen trading stocks online. Stock brokers looking at graphs, indexes and numbers on multiple computer screens. Colleagues in discussion in traders office. Business success concept.

Centessa plans $100m IPO to fund R&D and potential acquisiti...

Centessa has announced plans for a $100m US IPO just weeks after the company launched with $250m in private backing and an R&D powerhouse driven by the merger of 10 biotechs.

News

Young lonely man in a wheelchair on a balcony looking at the nature in the spring

Scotland opens door to Translarna for Duchenne muscular dyst...

A disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland gave a green light to use of PTC Therapeutics' Translarna for the first time.

News

NICE backs Sobi's Kineret for rare inflammatory disease

The UK's cost-effectiveness agency NICE has recommended that Sobi's Kineret can be used to treat NHS patients with Still's disease, a rare form of arthritis affecting children and adults.

CHMP backs Roche's Enspryng for rare nerve disease NMOSD

Calliditas eyes 2022 approval in EU for rare kidney disease ...

Jazz lifted by third EU approval for GW Pharma's Epidyolex

Centessa plans $100m IPO to fund R&D and potential acquisiti...

Scotland opens door to Translarna for Duchenne muscular dyst...

NICE backs Sobi's Kineret for rare inflammatory disease

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Rare Disease

Editor's Picks